Journey Medical Co. (NASDAQ:DERM - Get Free Report) CEO Claude Maraoui sold 49,271 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $5.01, for a total value of $246,847.71. Following the transaction, the chief executive officer now directly owns 2,003,147 shares of the company's stock, valued at approximately $10,035,766.47. This trade represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Claude Maraoui also recently made the following trade(s):
- On Friday, March 7th, Claude Maraoui sold 14,905 shares of Journey Medical stock. The shares were sold at an average price of $5.01, for a total value of $74,674.05.
- On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The stock was sold at an average price of $5.13, for a total value of $93,094.11.
- On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The stock was sold at an average price of $5.19, for a total transaction of $122,006.52.
Journey Medical Stock Performance
Shares of DERM stock traded up $0.15 during trading on Tuesday, reaching $5.15. 78,538 shares of the company's stock traded hands, compared to its average volume of 94,051. Journey Medical Co. has a 1 year low of $2.85 and a 1 year high of $6.89. The company has a market capitalization of $107.58 million, a P/E ratio of -5.48 and a beta of 0.97. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The firm's 50-day moving average is $4.62 and its 200 day moving average is $5.09.
Hedge Funds Weigh In On Journey Medical
A number of large investors have recently made changes to their positions in the stock. Tang Capital Management LLC bought a new position in Journey Medical in the 4th quarter worth about $6,747,000. PVG Asset Management Corp boosted its position in shares of Journey Medical by 5.7% in the third quarter. PVG Asset Management Corp now owns 167,545 shares of the company's stock valued at $947,000 after acquiring an additional 9,005 shares during the period. Geode Capital Management LLC increased its holdings in Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock worth $613,000 after acquiring an additional 12,882 shares during the period. Citadel Advisors LLC purchased a new stake in Journey Medical in the 4th quarter worth approximately $174,000. Finally, Kovitz Investment Group Partners LLC grew its position in shares of Journey Medical by 112.9% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock valued at $97,000 after purchasing an additional 13,105 shares in the last quarter. 7.25% of the stock is owned by institutional investors.
Journey Medical Company Profile
(
Get Free Report)
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Journey Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.
While Journey Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
